Numab

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

Total raised

€74M

€74,187,470

Funding rounds

Investors

distinct backers

Active since

2020-09

latest 2025-01

Funding by year

EUR raised per year

High confidence

Raise-next likelihood63

base rate 51% for Series C

Exit likelihood16

base rate 12% (2+ rounds)

Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

2 rounds

Date	Stage	Amount	Investors
2025-01-09	Series C	€53M	Cormorant Asset Management,Forbion,HBM Healthcare Investments,Novo Holdings	View deal →
2020-09-03	Series B	€21M	—	View deal →

same sector or country